Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

As GLP-1 medications like Ozempic, Wegovy, Zepbound, and Mounjaro gain popularity for weight loss, doctors are observing a ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat ...

Research shows that people who take these weight-loss medications may have a lower risk of dementia and numerous other health ...

Research identifies key factors affecting semaglutide initiation among obese individuals without diabetes, revealing ...

The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Co. (LLY), Exxon Mobil ...

About 140,400 obese patients in Massachusetts were prescribed medications like Wegovy and Zepbound in 2024, a 255 percent ...

In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help ...

Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December ...

Viking Therapeutics, Inc. offers promising advances in obesity and liver diseases, despite a recent stock drop over GLP-1 market concerns. Click for my VKTX update.

The study revealed that weight-loss drugs significantly benefit neurological and behavioral health, including decreased risks ...